Smaller pharmaceutical companies increase their chances of acquisitions

Biotech startups have historically relied on leading pharmaceutical companies to make acquisition offers. Now a new class of buyer is emerging.

Smaller pharmaceutical companies are joining the fray, offering entrepreneurs and venture capitalists another option for maintaining liquidity at a time when relatively few biotech companies are going public.